https://scholars.lib.ntu.edu.tw/handle/123456789/377124
標題: | Effects of monascin on anti-inflammation mediated by Nrf2 activation in advanced glycation end product-treated THP-1 monocytes and methylglyoxal-treated wistar rats | 作者: | TZU-MING PAN | 關鍵字: | methylglyoxal; monascin; nuclear factor-erythroid 2-related factor-2; receptor for advanced glycation end product; retinoic acid receptor-α; silymarin | 公開日期: | 2013 | 卷: | 61 | 期: | 6 | 起(迄)頁: | 1288-1298 | 來源出版物: | Journal of Agricultural and Food Chemistry | 摘要: | Hyperglycemia is associated with advanced glycation end products (AGEs). This study was designed to evaluate the inhibitory effects of monascin on receptor for advanced glycation end product (RAGE) signal and THP-1 monocyte inflammation after treatment with S100b, a specific ligand of RAGE. Monascin inhibited cytokine production by S100b-treated THP-1 monocytes via up-regulation of nuclear factor-erythroid 2-related factor-2 (Nrf2) and alleviated p47phox translocation to the membrane. Methylglyoxal (MG, 600 mg/kg bw) was used to induce diabetes in Wistar rats. Inhibitions of RAGE and p47phox by monascin were confirmed by peripheral blood mononuclear cells (PBMCs) of MG-induced rats. Silymarin (SM) was used as a positive control group. It was found that monascin promoted heme oxygenase-1 (HO-1) expression mediated by Nrf2. Suppressions of AGEs, tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-β) in serum of MG-induced rats were attenuated in the monascin administration group treated with retinoic acid (RA). RA treatment resulted in Nrf2 inactivation by increasing RA receptor-α (RARα) activity, suggesting that RA acts as an inhibitor of Nrf2. The results showed that monascin exerted anti-inflammatory and antioxidative effects mediated by Nrf2 to prevent the development of diseases such as type 2 diabetes caused by inflammation. ? 2013 American Chemical Society. |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-84873683228&partnerID=MN8TOARS http://scholars.lib.ntu.edu.tw/handle/123456789/377124 |
DOI: | 10.1021/jf305067n | SDG/關鍵字: | Advanced glycation end products; Methylglyoxal; Monascin; nuclear factor-erythroid 2-related factor-2; Retinoic acid receptors; Silymarin; Design; Flavonoids; Glycosylation; Pathology; Porphyrins; Rats; Body fluids; advanced glycation end product; antiinflammatory agent; fused heterocyclic rings; methylglyoxal; monascin; transcription factor Nrf2; animal; article; cell line; drug effect; genetics; human; immunology; male; monocyte; non insulin dependent diabetes mellitus; rat; upregulation; Wistar rat; Animals; Anti-Inflammatory Agents; Cell Line; Diabetes Mellitus, Type 2; Glycosylation End Products, Advanced; Heterocyclic Compounds, 3-Ring; Humans; Male; Monocytes; NF-E2-Related Factor 2; Pyruvaldehyde; Rats; Rats, Wistar; Up-Regulation; Rattus; Rattus norvegicus |
顯示於: | 生化科技學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。